Javascript must be enabled to continue!
Ni(1−x)Pdx Alloyed Nanostructures for Electrocatalytic Conversion of Furfural into Fuels
View through CrossRef
A continuous electrocatalytic reactor offers a promising method for producing fuels and value-added chemicals via electrocatalytic hydrogenation of biomass-derived compounds. However, such processes require a better understanding of the impact of different types of active electrodes and reaction conditions on electrocatalytic biomass conversion and product selectivity. In this work, Ni1−xPdx (x = 0.25, 0.20, and 0.15) alloyed nanostructures were synthesized as heterogeneous catalysts for the electrocatalytic conversion of furfural. Various analytical tools, including XRD, SEM, EDS, and TEM, were used to characterize the Ni1−xPdx catalysts. The alloyed catalysts, with varying Ni to Pd ratios, showed a superior electrocatalytic activity of over 65% for furfural conversion after 4.5 h of reaction. In addition, various experimental parameters on the furfural conversion reactions, including electrolyte pH, furfural (FF) concentration, reaction time, and applied potential, were investigated to tune the hydrogenated products. The results indicated that the production of 2-methylfuran as a primary product (S = 29.78% after 1 h), using Ni0.85Pd0.15 electrocatalyst, was attributed to the incorporation of palladium and thus the promotion of water-assisted proton transfer processes. Results obtained from this study provide evidence that alloying a common catalyst, such as Ni with small amounts of Pd metal, can significantly enhance its electrocatalytic activity and selectivity.
Title: Ni(1−x)Pdx Alloyed Nanostructures for Electrocatalytic Conversion of Furfural into Fuels
Description:
A continuous electrocatalytic reactor offers a promising method for producing fuels and value-added chemicals via electrocatalytic hydrogenation of biomass-derived compounds.
However, such processes require a better understanding of the impact of different types of active electrodes and reaction conditions on electrocatalytic biomass conversion and product selectivity.
In this work, Ni1−xPdx (x = 0.
25, 0.
20, and 0.
15) alloyed nanostructures were synthesized as heterogeneous catalysts for the electrocatalytic conversion of furfural.
Various analytical tools, including XRD, SEM, EDS, and TEM, were used to characterize the Ni1−xPdx catalysts.
The alloyed catalysts, with varying Ni to Pd ratios, showed a superior electrocatalytic activity of over 65% for furfural conversion after 4.
5 h of reaction.
In addition, various experimental parameters on the furfural conversion reactions, including electrolyte pH, furfural (FF) concentration, reaction time, and applied potential, were investigated to tune the hydrogenated products.
The results indicated that the production of 2-methylfuran as a primary product (S = 29.
78% after 1 h), using Ni0.
85Pd0.
15 electrocatalyst, was attributed to the incorporation of palladium and thus the promotion of water-assisted proton transfer processes.
Results obtained from this study provide evidence that alloying a common catalyst, such as Ni with small amounts of Pd metal, can significantly enhance its electrocatalytic activity and selectivity.
Related Results
Mechanistic Investigations for Electrocatalytic Oxidation of Furfural Using Density Functional Theory
Mechanistic Investigations for Electrocatalytic Oxidation of Furfural Using Density Functional Theory
Mechanistic Investigations for Electrocatalytic Oxidation of Furfural Using Density Functional Theory
Naveen Agrawal,a Li Gong,a,b Alex Roman,c
...
Valorization of low concentration sugar side-stream from dissolving pulp production
Valorization of low concentration sugar side-stream from dissolving pulp production
Among the platform chemicals that can be produced from lignocellulosic biomass, furfural
(FUR) constitutes a promising intermediate that can be processed into a variety of advance...
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract
Background While HER2-directed agents are most often used for treating breast cancer, there is increasing evidence that these therapies may be of value in o...
Protectin DX resolves fracture-induced postoperative pain in mice via neuronal signaling and GPR37-activated macrophage efferocytosis
Protectin DX resolves fracture-induced postoperative pain in mice via neuronal signaling and GPR37-activated macrophage efferocytosis
Abstract
Protectin DX (PDX) is a member of the superfamily of specialized pro-resolving mediators (SPMs) and exerts anti-inflammatory actions in ...
Long-Term Dormant Cells in Acute Myeloid Leukemia Patient-Derived Xenografts Display Reversible Treatment Resistance, but Are Not Enriched for Leukemia-Initiating Cells
Long-Term Dormant Cells in Acute Myeloid Leukemia Patient-Derived Xenografts Display Reversible Treatment Resistance, but Are Not Enriched for Leukemia-Initiating Cells
Abstract
Introduction
Leukemia-initiating cells (LIC) are considered the source of therapy resistance and relapse, including in acute myeloid leukemia...
FURFURAL BERBASIS TANDAN KOSONG KELAPA SAWIT
FURFURAL BERBASIS TANDAN KOSONG KELAPA SAWIT
Furfural dapat diproduksi menggunakan bahan baku yang mengandung pentosan, diantaranya tandan kosong kelapa sawit. Furfural adalah senyawa aromatik aldehid bewarna kuning bening da...
Abstract 1697: Humanized immune-oncology mouse models
Abstract 1697: Humanized immune-oncology mouse models
Abstract
The recent clinical success of immune checkpoint modulators has stimulated immune-oncology research leading to the identification of new tumor immunology ta...
Data from Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
Data from Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
<div>Abstract<p><b>Purpose:</b> Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with few therapeutic options. The tumor–stromal interf...

